Your email has been successfully added to our mailing list.

×
0.000308975745403924 -0.000463463618105996 0 0.000772439363509921 0.000617951490807849 0.0033214892630929 0.00702919820794065 0.00741541788969572
Stock impact report

8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030 [Yahoo! Fin...

AstraZeneca PLC - American Depositary Shares (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
Company Research Source: Yahoo! Finance
The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook. Up until recently, there was only one marketed pharmaceutical product indicated for the prevention of RSV infections. AstraZeneca/AbbVie's Synagis (palivizumab), a prophylactic, humanized, mouse monoclonal antibody (mAb), has been indicated for the prophylaxis of RSV in infants at a high risk of severe infection since 1998. Synagis is licensed in all of the 8MM and has been shown to be effective for preventing severe RSV infection in infants and children with prematurity, bronchopulmonary dysplasia (BPD), and congenital heart defects (CHD). However, the 20-day half-life of Synagis, requirement for monthly dosing during the RSV season, and prohibitively high cost has led to its decreased use over time. Signi Show less Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AZN alerts
Opt-in for
AZN alerts

from News Quantified
Opt-in for
AZN alerts

from News Quantified